DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular

Clinical Science

Volumn 122, Issue 10, 2012, Pages 449-457

  Buchanan, Christina M ^a   Shih, Jen Hsing ^a   Astin, Jonathan W ^a   Rewcastle, Gordon W ^a,b   Flanagan, Jack U ^a,b   Crosier, Philip S ^a   Shepherd, Peter R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

5,6 dimethylxanthenone 4 acetic acid (DMXAA); Angiogenesis; Antivascular; Kinase inhibition; Screening; Vascular endothelial growth factor receptor (VEGFR)

Indexed keywords

2 METHYL XANTHENONE 4 ACETIC ACID; 6 METHYL XANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; TIVOZANIB; UNCLASSIFIED DRUG; VADIMEZAN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; EMBRYO; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; ZEBRA FISH;

ANIMALS; HUMANS; MODELS, MOLECULAR; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XANTHONES; ZEBRAFISH;

EID: 84858736660     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110412     Document Type: Article

References (63)

1. Baguley, B. C. (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol. 4, 141-148
2. Laws, A. L., Matthew, A. M., Double, J. A. and Bibby, M. C. (1995) Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 71, 1204-1209
3. Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F. and Roberts, T. M. (2005) The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 102, 18443-18448
4. Oehler, C., O'Donoghue, J. A., Russell, J., Zanzonico, P., Lorenzen, S., Ling, C. C. and Carlin, S. (2011) 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J. Nucl. Med. 52, 437-444
5. Seshadri, M. and Bellnier, D. A. (2009) The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. Photochem. Photobiol. 85, 50-56
6. Seshadri, M. and Ciesielski, M. J. (2009) MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas. J. Cereb. Blood Flow Metab. 29, 1373-1382
7. Seshadri, M. and Toth, K. (2009) Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic acid in an orthotopic model of human head and neck cancer. Transl. Oncol. 2, 121-127
8. Ching, L. M., Zwain, S. and Baguley, B. C. (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br. J. Cancer 90, 906-910
9. Marrelli, M., Conforti, F., Statti, G. A., Cachet, X., Michel, S., Tillequin, F. and Menichini, F. (2011) Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4. Curr. Med. Chem. 18, 3035-3081
10. Shi, W. and Siemann, D. W. (2005) Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 19, 1045-1050
11. Lorusso, P. M., Boerner, S. A. and Hunsberger, S. (2011) Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? J. Clin. Oncol. 29, 2952-2955
12. Hida, T., Tamiya, M., Nishio, M., Yamamoto, N., Hirashima, T., Horai, T., Tanii, H., Shi, M. M., Kobayashi, K. and Horio, Y. (2011) Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer. Cancer Sci. 102, 845-851
13. McKeage, M. J., Fong, P., Jeffery, M., Baguley, B. C., Kestell, P., Ravic, M. and Jameson, M. B. (2006) 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin. Cancer Res. 12, 1776-1784
14. Rustin, G. J., Bradley, C., Galbraith, S., Stratford, M., Loadman, P., Waller, S., Bellenger, K., Gumbrell, L., Folkes, L. and Halbert, G. (2003) 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br. J. Cancer 88, 1160-1167
15. Galbraith, S. M., Rustin, G. J., Lodge, M. A., Taylor, N. J., Stirling, J. J., Jameson, M., Thompson, P., Hough, D., Gumbrell, L. and Padhani, A. R. (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J. Clin. Oncol. 20, 3826-3840
16. Ching, L. M., Cao, Z., Kieda, C., Zwain, S., Jameson, M. B. and Baguley, B. C. (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 86, 1937-1942
17. Jameson, M. B., Thompson, P. I., Baguley, B. C., Evans, B. D., Harvey, V. J., Porter, D. J., McCrystal, M. R., Small, M., Bellenger, K., Gumbrell, L. et al. (2003) Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br. J. Cancer 88, 1844-1850
18. McKeage, M. J., Reck, M., Jameson, M. B., Rosenthal, M. A., Gibbs, D., Mainwaring, P. N., Freitag, L., Sullivan, R. and Von Pawel, J. (2009) Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 65, 192-197
19. McKeage, M. J., Von Pawel, J., Reck, M., Jameson, M. B., Rosenthal, M. A., Sullivan, R., Gibbs, D., Mainwaring, P. N., Serke, M., Lafitte, J. J. et al. (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br. J. Cancer 99, 2006-2012
20. Pili, R., Rosenthal, M. A., Mainwaring, P. N., Van Hazel, G., Srinivas, S., Dreicer, R., Goel, S., Leach, J., Wong, S. and Clingan, P. (2010) Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin. Cancer Res. 16, 2906-2914
21. Lara, Jr, P. N., Douillard, J. Y., Nakagawa, K., von Pawel, J., McKeage, M. J., Albert, I., Losonczy, G., Reck, M., Heo, D. S., Fan, X. et al. (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J. Clin. Oncol. 29, 2965-2971
22. Jameson, M. B., Sharp, D. M., Sissingh, J. I., Hogg, C. R., Thompson, P. I., McKeage, M. J., Jeffery, M., Waller, S., Acton, G., Green, C. and Baguley, B. C. (2009) Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. Invest. Ophthalmol. Visual Sci. 50, 2553-2559
23. Favot, L., Keravis, T., Holl, V., Le Bec, A. and Lugnier, C. (2003) VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb. Haemostasis 90, 334-343
24. Sahara, M., Sata, M., Morita, T., Nakajima, T., Hirata, Y. and Nagai, R. (2010) A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway. Arterioscler. Thromb. Vasc. Biol. 30, 1315-1324
25. Atwell, G. J., Rewcastle, G.W., Baguley, B. C. and Denny, W. A. (1990) Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids. J. Med. Chem. 33, 1375-1379
26. Rewcastle, G. W., Atwell, G. J., Baguley, B. C., Boyd, M., Thomsen, L. L., Zhuang, L. and Denny, W. A. (1991) Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. J. Med. Chem. 34, 2864-2870
27. Rewcastle, G. W., Atwell, G. J., Li, Z. A., Baguley, B. C. and Denny, W. A. (1991) Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem. 34, 217-222
28. Rewcastle, G. W., Atwell, G. J., Palmer, B. D., Boyd, P. D., Baguley, B. C. and Denny, W. A. (1991) Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid. J. Med. Chem. 34, 491-496
29. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I., Arthur, J. S., Alessi, D. R. and Cohen, P. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315
30. Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M. and Knight, Z. A. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691-699
31. Lawson, N. D. and Weinstein, B. M. (2002) In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev. Biol. 248, 307-318
32. Jamieson, S., Flanagan, J. U., Kolekar, S., Buchanan, C., Kendall, J. D., Lee, W. J., Rewcastle, G. W., Denny, W. A., Singh, R., Dickson, J. et al. (2011) A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem. J. 438, 53-62
33. Hasegawa, M., Nishigaki, N.,Washio, Y., Kano, K., Harris, P. A., Sato, H., Mori, I., West, R. I., Shibahara, M., Toyoda, H. et al. (2007) Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR2 tyrosine kinase receptors. J. Med. Chem. 50, 4453-4470
34. Philpott, M., Baguley, B. C. and Ching, L. M. (1995) Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 36, 143-148
35. Zhao, L., Marshall, E. S., Kelland, L. R. and Baguley, B. C. (2007) Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Invest. New Drugs 25, 271-276
36. Gobbi, S., Belluti, F., Bisi, A., Piazzi, L., Rampa, A., Zampiron, A., Barbera, M., Caputo, A. and Carrara, M. (2006) New derivatives of xanthenone-4-acetic acid: synthesis, pharmacological profile and effect on TNF-α and NO production by human immune cells. Bioorg. Med. Chem. 14, 4101-4109
37. Barbera, M., Kettunen, M. I., Caputo, A., Hu, D. E., Gobbi, S., Brindle, K. M. and Carrara, M. (2009) Immune-modulating and anti-vascular activities of two xanthenone acetic acid analogues: A comparative study to DMXAA. Int. J. Oncol. 34, 273-279
38. Jameson, M. B., Baguley, B. C., Kestell, P., Zhao, L., Paxton, J. W., Thompson, P. I. and Waller, S. (2007) Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. Cancer Chemother. Pharmacol. 59, 681-687
39. De Luca, A. and Normanno, N. (2010) Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. Drugs 13, 636-645
40. Mukherjee, S., Tessema, M. andWandinger-Ness, A. (2006) Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ. Res. 98, 743-756
41. Jameson, M. B. and Head, M. (2011) Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA). Expert Opin. Drug Metab. Toxicol. 7, 1315-1326
42. Zhao, L., Ching, L. M., Kestell, P., Kelland, L. R. and Baguley, B. C. (2005) Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int. J. Cancer 116, 322-326
43. Rewcastle, G.W., Atwell, G. J., Baguley, B. C., Calveley, S. B. and Denny, W. A. (1989) Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J. Med. Chem. 32, 793-799
44. Cozza, G., Mazzorana, M., Papinutto, E., Bain, J., Elliott, M., di Maira, G., Gianoncelli, A., Pagano, M. A., Sarno, S., Ruzzene, M. et al. (2009) Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem. J. 421, 387-395
45. Trembley, J. H., Chen, Z., Unger, G., Slaton, J., Kren, B. T., Van Waes, C. and Ahmed, K. (2010) Emergence of protein kinase CK2 as a key target in cancer therapy. BioFactors 36, 187-195
46. Huertas, D., Soler, M., Moreto, J., Villanueva, A., Martinez, A., Vidal, A., Charlton, M., Moffat, D., Patel, S., McDermott, J. et al. (2011) Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene, doi: 10.1038/onc.2011.335
47. Dar, A. A., Goff, L.W., Majid, S., Berlin, J. and El-Rifai,W. (2010) Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol. Cancer Ther. 9, 268-278
48. Dodson, C. A., Kosmopoulou, M., Richards, M. W., Atrash, B., Bavetsias, V., Blagg, J. and Bayliss, R. (2010) Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. Biochem. J. 427, 19-28
49. Nawijn, M. C., Alendar, A. and Berns, A. (2011) For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev. Cancer 11, 23-34
50. Burns, C. J. and Wilks, A. F. (2011) c-FMS inhibitors: a patent review. Expert Opin. Ther. Pat. 21, 147-165
51. Koch, S., Tugues, S., Li, X., Gualandi, L. and Claesson-Welsh, L. (2011) Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 437, 169-183
52. Brodeur, G. M., Minturn, J. E., Ho, R., Simpson, A. M., Iyer, R., Varela, C. R., Light, J. E., Kolla, V. and Evans, A. E. (2009) Trk receptor expression and inhibition in neuroblastomas. Clin. Cancer Res. 15, 3244-3250
53. Zippo, A., De Robertis, A., Bardelli, M., Galvagni, F. and Oliviero, S. (2004) Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 103, 4536-4544
54. Ching, L. M., Joseph, W. R. and Baguley, B. C. (1992) Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid. Biochem. Pharmacol. 44, 192-195
55. Cao, Z., Baguley, B. C. and Ching, L. M. (2001) Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res. 61, 1517-1521
56. Czabanka, M., Vinci, M., Heppner, F., Ullrich, A. and Vajkoczy, P. (2009) Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int. J. Cancer 124, 1293-1300
57. Hillman, G. G., Singh-Gupta, V., Al-Bashir, A. K., Yunker, C. K., Joiner, M. C., Sarkar, F. H., Abrams, J. and Haacke, E. M. (2011) Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor. Transl. Oncol. 4, 110-121
58. O'Connor, J. P., Carano, R. A., Clamp, A. R., Ross, J., Ho, C. C., Jackson, A., Parker, G. J., Rose, C. J., Peale, F. V., Friesenhahn, M. et al. (2009) Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin. Cancer Res. 15, 6674-6682
59. Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V. et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147
60. Crescenzi, M., Persano, L., Esposito, G., Zulato, E., Borsi, L., Balza, E., Ruol, A., Ancona, E., Indraccolo, S. and Amadori, A. (2011) Vandetanib improves anti-tumor effects of L19mTNFα in xenograft models of esophageal cancer. Clin. Cancer Res. 17, 447-458
61. Cee, V. J., Cheng, A. C., Romero, K., Bellon, S., Mohr, C., Whittington, D. A., Bak, A., Bready, J., Caenepeel, S., Coxon, A. et al. (2009) Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase. Bioorg. Med. Chem. Lett. 19, 424-427
62. Harris, P. A., Cheung, M., Hunter, III, R. N., Brown, M. L., Veal, J. M., Nolte, R. T.,Wang, L., Liu, W., Crosby, R. M., Johnson, J. H. et al. (2005) Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J. Med. Chem. 48, 1610-1619
63. Miyazaki, Y., Matsunaga, S., Tang, J., Maeda, Y., Nakano, M., Philippe, R. J., Shibahara, M., Liu, W., Sato, H., Wang, L. and Nolte, R. T. (2005) Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg. Med. Chem. Lett. 15, 2203-2207